| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/25/2008 | US20080234268 Effective for prophylaxis and treatment of diseases, such as ("c-Met") hepatocyte growth factor receptor mediated diseases; N-(4-(3-amino-1H-indazol-4-yl)-3-fluorophenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide; treatment of neoplasia selected from lung, breast, colon cancer |
| 09/25/2008 | US20080234266 Squaric Acid Derivatives II |
| 09/25/2008 | US20080234264 Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
| 09/25/2008 | US20080234263 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide |
| 09/25/2008 | US20080234262 For treating Mammalian Target of Rapamycin (mTOR)-related disorders and phosphatidylinositol-3 kinase ("PI3K")-related disorders; N-{3-[1-(1-benzylpiperidin-4-yl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-6-yl]phenyl}-N'-methylurea; anticarcinogenic agents, antiinflammatory agents |
| 09/25/2008 | US20080234258 Dihydroxyanthraquinones and Their Use |
| 09/25/2008 | US20080234254 anticarcinogenic agents for treating leukaemia, non-small cell lung cancers, colonic cancers, breast cancers, ovarian cancers, renal cancers and melanoma; in vivo hydrolysable ester or amide; N-(2-amino-phenyl)-4-[1-(3,4-dihydroisoquinolin-2(1H)-ylmethyl)vinyl]benzamide; solid phase synthesis |
| 09/25/2008 | US20080234246 Benzoquinone imine-containing ansamycins and its acylation or alkylation derivatives; cellular proliferation, hyperproliferation; increase the bioavailability and reduce the toxicity associated with the natural product |
| 09/25/2008 | US20080234244 Inhibit growth of cancer cells; modulate signal molecules Raf, Mek1, Mek2, Erk1, Erk2 and STAT3; purafied nutraceutical extract; |
| 09/25/2008 | US20080234232 Methods and compositions for targeting AFAP |
| 09/25/2008 | US20080234229 Boronate naphthalene derivaties and other active compounds; pharmaceutical; cosmeceutical; modulators of gene expression; interfering with cellular signal transduction cascades |
| 09/25/2008 | US20080234216 TGF-beta type receptor cDNAs encoded products and uses therefor |
| 09/25/2008 | US20080234214 Seven or more contiguous ribose groups linked by achiral 5' to 3' internucleoside phosphate linkages; antisense agents for gene expression inhibition of a wide variety of pathological disorders such as autoimmune diseases; suitable for oral administration |
| 09/25/2008 | US20080234205 Antineoplastic peptides |
| 09/25/2008 | US20080234204 Methods for evaluating and implementing prostate disease treatments |
| 09/25/2008 | US20080234199 Chemical Compounds |
| 09/25/2008 | US20080234187 In particular amidated, acetylated, phosphorylated and/or glycosylated derivatives; diagnostic agents including a nucleic acid or messenger RNA coding for the cytokine; isolated from human hemofiltrate |
| 09/25/2008 | US20080234183 Predicting or designing, detecting, and/or verifying a novel cell-penetrating peptide that mimics cellular effector activity; vectors; treating and/or preventing infectious diseases, diabetes type I and II, Alzheimer's Disease, Parkinson's Disease, and cancer. |
| 09/25/2008 | US20080234132 Inhibitors of DNA gyrase; for inhibiting bacterial infections, treating cancer, controlling plant growth and seed germination |
| 09/25/2008 | US20080233651 Method and medicament for inhibiting the expression of a given gene |
| 09/25/2008 | US20080233646 Human DR4 antibodies and uses thereof |
| 09/25/2008 | US20080233644 Chimeric Transcription Factor Decoy Oligonucleotides |
| 09/25/2008 | US20080233637 Melanoma antigens and their use in diagnostic and therapeutic methods |
| 09/25/2008 | US20080233556 Cytotonic protein and utlization thereof |
| 09/25/2008 | US20080233218 Administering therapeutically effective amounts of supercritical extracts of rosemary, turmeric, oregano and ginger and hydroalcoholic extracts of holy basil, ginger, turmeric, Scutellaria baicalensis, rosemary, green tea, huzhang, Chinese goldthread, and barberry; modules gene expression of interleukins |
| 09/25/2008 | US20080233214 Demonstrate cytotoxic activity against a variety of cell types exhibiting hyperproliferative cell division; anticarcinogenic agents; ovarian cancer; naphtho(2,3-b)furan derivatives |
| 09/25/2008 | US20080233208 Administering a composition of a 3,4,5-trimethoxyl phenyl ethyl-2-methoxy-phenol; enhancing the efficacy of chemotherapeutics without adding to its toxicity |
| 09/25/2008 | US20080233207 Aqueous solution of an inorganic mercury (II) containing compound, a buffer and a salt; mercury acetate, sodium acetate and sodium chloride |
| 09/25/2008 | US20080233185 Using dimethyl fumarate and/or diethyl fumarate, calcium alkyl fumarate, calcium methyl fumarate and/or calcium ethyl fumarate, zinc methyl fumarate and/or zinc ethyl fumarate, methyl hydrogen fumarate and/or ethyl hydrogen fumarate; sclerodermia, osteochondritis syphilitica (Wegener's disease) |
| 09/25/2008 | US20080233183 Liposomal concentrate of a phospholipid, lipophilic bioactive agent, a solubilizer, a carrier permeation enhancer; analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics |
| 09/25/2008 | US20080233149 Use of Erythropoietin for Enhancing Immune Responses and for Treatment of Lymphoproliferative Disorders |
| 09/25/2008 | US20080233139 Polypeptide comprising major histocompatibility complex epitopes for use in targeting and destroying tumor cells |
| 09/25/2008 | US20080233136 Biologically Active Peptides |
| 09/25/2008 | US20080233135 Cobalamin taxane bioconjugates |
| 09/25/2008 | US20080233133 Specified complementary determining region (CRD) amino acid sequences; specific binding activity for a cryptic collagen epitope; angiogenesis inhibition, antimetastasis, and tumor-targeted therapy uses |
| 09/25/2008 | US20080233127 Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| 09/25/2008 | US20080233125 Antibodies target laminin 5 alpha 3 G4-G5 domain |
| 09/25/2008 | US20080233121 Therapeutic treatments based on administration of small RNA fragments |
| 09/25/2008 | US20080233120 Complementarity determining region (CDR); cancer, rheumatoid arthritis; immunology |
| 09/25/2008 | US20080233108 Methods for detecting and inhibiting angiogenesis using antagonists |
| 09/25/2008 | US20080233078 Therapeutic polyesters and polyamides |
| 09/25/2008 | US20080233046 Antisense agents; RNA interference; gene expression inhibition; hybridomas; hormone replacement therapy |
| 09/25/2008 | DE102007013856A1 Substituierte Tetrahydropyrrolochinoline Substituted Tetrahydropyrrolochinoline |
| 09/25/2008 | DE102007013855A1 Substituierte Tetrahydrochinoline Substituted tetrahydroquinolines |
| 09/25/2008 | DE102007013854A1 Tetrahydrochinoline Tetrahydroquinolines |
| 09/25/2008 | DE102007013812A1 New 1-azacycloalkylimidazole derivatives useful for treating cancer, malaria, cardiovascular diseases or Alzheimer's disease |
| 09/25/2008 | DE102007013765A1 Lejimalid Analoga und Verwendung davon Lejimalid analogues and use thereof |
| 09/25/2008 | CA2823407A1 Topical formulations having enhanced bioavailability |
| 09/25/2008 | CA2681505A1 Iejimalid analoga and uses thereof |
| 09/25/2008 | CA2681501A1 Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| 09/25/2008 | CA2681466A1 Quinoline derivatives, pharmaceutical compositions comprising them, and their use in treating central nervous system and peripheral diseases |
| 09/25/2008 | CA2681326A1 Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| 09/25/2008 | CA2681261A1 Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer |
| 09/25/2008 | CA2681260A1 Substituted tetrahydropyrroloquinolines |
| 09/25/2008 | CA2681256A1 Substituted pyranyl quinolines |
| 09/25/2008 | CA2681015A1 Inhibitors of focal adhesion kinase |
| 09/25/2008 | CA2680757A1 Substituted pyrimidodiazepines useful as plk1 inhibitors |
| 09/25/2008 | CA2680397A1 Novel adenine compound |
| 09/25/2008 | CA2680368A1 A method of treating malignant mesothelioma |
| 09/25/2008 | CA2680239A1 Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors |
| 09/25/2008 | CA2680006A1 Weekly administration of dipeptidyl peptidase inhibitors |
| 09/25/2008 | CA2679344A1 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof |
| 09/25/2008 | CA2676954A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 09/25/2008 | CA2653226A1 Liposomes and immunopotentiating compositions containing the same |
| 09/24/2008 | EP1972633A1 Antitumour compounds |
| 09/24/2008 | EP1972631A1 Imidazopyridazines as PI3K lipid kinase inhibitors |
| 09/24/2008 | EP1972617A1 Compounds having aryl-sulphonamidic structure useful as metalloproteases inhibitors |
| 09/24/2008 | EP1972611A1 Aryl dihydro-naphthalene compounds, their preparation and their use as akt inhibitor for the prevention and treatment of cancer |
| 09/24/2008 | EP1972338A1 Anti-infective agents |
| 09/24/2008 | EP1971680A1 Method for generating dendritic cells employing decreased temperature |
| 09/24/2008 | EP1971618A2 Modulators of hypoxia inducible factor-1 and related uses |
| 09/24/2008 | EP1971613A1 Crystalline form of vinflunine ditartrate |
| 09/24/2008 | EP1971604A2 Pyrrolo-pyridine derivatives for the treatment of cancer diseases |
| 09/24/2008 | EP1971601A2 N4-phenyl-quinazoline-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases |
| 09/24/2008 | EP1971594A2 Substituted pyrazalones |
| 09/24/2008 | EP1971588A1 Tiglien-3-one derivatives |
| 09/24/2008 | EP1971578A1 21-deoxymacbecin analogues useful as antitumor agents |
| 09/24/2008 | EP1971401A2 METHODS OF USING THE CALCINEURIN A VARIANT Cnaß1 |
| 09/24/2008 | EP1971371A2 Cancer therapies and pharmaceutical compositions used therein |
| 09/24/2008 | EP1971357A2 Use of tpp ii inhibitors in combination with gamma-irradiation for the treatment of cancer |
| 09/24/2008 | EP1971338A2 Combination of zd6474 and pemetrexed |
| 09/24/2008 | EP1906950A4 Ansamycin formulations and methods of use thereof |
| 09/24/2008 | EP1885725B1 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents |
| 09/24/2008 | EP1799227A4 Therapeutic agents targeting the nc ca-atp channel and methods of use thereof |
| 09/24/2008 | EP1653964B1 Cancer combination therapy comprising azd2171 and zd1839 |
| 09/24/2008 | EP1572299B1 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 09/24/2008 | EP1537096B1 Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics |
| 09/24/2008 | EP1513520B1 Substituted pyrrolines as kinase inhibitors |
| 09/24/2008 | EP1509528B1 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 09/24/2008 | EP1408986B1 Proteomimetic compounds and methods |
| 09/24/2008 | EP1381599B1 Quinazoline derivatives |
| 09/24/2008 | EP1365762B1 Method for increasing leptin levels using nicotinic acid compounds |
| 09/24/2008 | EP1322650B1 Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
| 09/24/2008 | CN101273142A Methods of modulating SMYD3 for treatment of cancer |
| 09/24/2008 | CN101273132A Compositions and methods for treating breast cancer |
| 09/24/2008 | CN101273130A Nucleic acid agents for downregulating H19, and methods of using same |
| 09/24/2008 | CN101273064A Anti-TrkB monoclonal antibodies and uses thereof |
| 09/24/2008 | CN101273038A Macrocylic inhibitors of hepatitis C virus |
| 09/24/2008 | CN101273033A 4- (iH-indazol-s-yl-amino)-quinazoline compounds as ERBB receptor tyrosine kinase inhibitors for the treatment of cancer |
| 09/24/2008 | CN101272766A Composition for administration to mammals or humans |